Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DUX4 Transcript Knockdown with Antisense 2′-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy

14 Oct 2020

Abstract excerpt

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder characterized by a progressive, asymmetric weakening of muscles, starting with those in the upper body. It is caused by aberrant expression of the double homeobox protein 4 gene (DUX4) in skeletal muscle. FSHD is currently incurable. We propose to develop a therapy for FSHD using antisense 2'-O-methoxyethyl (2'-MOE) gapmers, to knock...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Muscle Physiology and Disorders
Share to Neurogenetic and Muscular Disorders Research
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33068777
DOI: 10.1016/j.ymthe.2020.10.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DUX4 Transcript Knockdown with Antisense 2′-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular DystrophyPMID 33068777Read ↗

Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical LandscapeSemantic proximity Read ↗

Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophySemantic proximity Read ↗

RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD TherapySemantic proximity Read ↗

Genetic Approaches for the Treatment of Facioscapulohumeral Muscular DystrophySemantic proximity Read ↗

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible TreatmentsSemantic proximity Read ↗

Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 ExpressionSemantic proximity Read ↗

Facioscapulohumeral Muscular Dystrophy.Semantic proximity Read ↗

FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?Semantic proximity Read ↗

Facioscapulohumeral Dystrophy: Molecular Basis and Therapeutic Opportunities.Semantic proximity Read ↗

Antisense targeting of 3′ end elements involved inDUX4mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approachSemantic proximity Read ↗

Targeted <i>DUX4</i> base editing improves muscle function in an iPSC-derived model of childhood-onset FSHDSemantic proximity Read ↗

The FSHD atrophic myotube phenotype is caused by DUX4 expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.